For a long time it has been known that the protein TOR – Target of Rapamycin – controls cell growth and is involved in the development of diseases such as cancer and diabetes. Researchers at the University of Basel’s Biozentrum together with scientists from ETH Zurich have now examined the structure of mammalian TOR complex 1 (mTORC1) in more detail. The scientists have revealed its unique architecture in their latest publication in “Science”.
About 25 years ago, Prof. Michael Hall discovered the protein “Target of Rapamycin” (TOR) at the Biozentrum. It is one of the most studied proteins of the protein kinase family, an important family of regulatory proteins that control many cellular processes.
TOR, in mammals called mTOR, is very important for cellular signalling and is implicated in various diseases such as cancer, diabetes, and neurodegeneration. Several mTOR inhibitors have already been approved for therapeutic use, in particular in the treatment of cancer and allograft rejection.
However, despite extensive research on TOR over the last decades, attempts to uncover the detailed structure of the protein kinase and its partners have been unsuccessful. By combining crystallographic methods with cryo-electron microscopy, Prof. Timm Maier’s team together with researchers of the ETH Zurich have now been able to provide unprecedented insight into the architecture of the protein complex mTORC1.
Structure of mTORC1 elucidated
In the cell, the protein kinase mTOR is found in two structurally and functionally distinct protein complexes termed mTORC1 and mTORC2 in mammals. Both complexes are giant protein structures consisting of mTOR and other accompanying proteins. In these two configurations the protein kinase carries out various functions such as the control of cell size and growth, as well as the regulation of metabolism and energy balance.
mTOR itself is one of the largest proteins in the cell and when combined with other proteins even larger. This makes it quite difficult to investigate its structure. “The partner proteins of mTOR have already been identified in earlier biochemical studies”, says Maier.
“However, it has remained unclear how the proteins interact precisely.” After more than three years of work, the scientists led by Maier have succeeded in isolating mTORC1 in the quality required for high-resolution cryo-electron microscopy. Using X-ray crystallography they have also been able to determine the structure of the protein Raptor, the second major component of mTORC1.
Accompanying proteins important for function
"Although there is much known about mTORC1, our study revealed surprising new insight”, states Maier. "The architecture of this huge protein complex is quite exceptional. We could determine the precise interaction sites of the partner proteins and how they are arranged, and thus elucidate the function of the individual partners.” In fact, each protein plays an important role in the regulation of the activity of the entire complex and the intracellular signalling cascade.
More than the sum of its parts
With their study, the researchers have provided the basis for further investigations. Now the researchers will be able to investigate the function of each individual protein in the complex in more detail. “But it doesn’t make sense to examine the individual components alone, as the interactions of all the proteins in the complex are critical for its function”, explains Maier. “The whole is much more than the sum of its parts.” The finely tuned regulation of mTOR activity is very important because even the smallest disturbances can have serious consequences. Thus, dysregulation in the mTOR signalling pathways plays a role in the development of a number of diseases.
Christopher H.S. Aylett, Evelyn Sauer, Stefan Imseng, Daniel Boehringer, Michael N. Hall, Nenad Ban and Timm Maier
Architecture of Human mTOR Complex 1
Science, published online 17 December 2015.
Prof. Dr. Timm Maier, University of Basel, Biozentrum, tel. +41 61 267 21 76, email: email@example.com
Dr. Katrin Bühler, University of Basel, Biozentrum, Communications, tel. +41 61 267 09 74, email: firstname.lastname@example.org
Katrin Bühler | Universität Basel
Gut microbiome regulates the intestinal immune system, researchers find
19.12.2018 | Brown University
Greener days ahead for carbon fuels
19.12.2018 | DOE/Lawrence Berkeley National Laboratory
Different eras of civilization are defined by the discovery of new materials, as new materials drive new capabilities. And yet, identifying the best material...
Researchers from the University of Basel have reported a new method that allows the physical state of just a few atoms or molecules within a network to be controlled. It is based on the spontaneous self-organization of molecules into extensive networks with pores about one nanometer in size. In the journal ‘small’, the physicists reported on their investigations, which could be of particular importance for the development of new storage devices.
Around the world, researchers are attempting to shrink data storage devices to achieve as large a storage capacity in as small a space as possible. In almost...
The more objects we make "smart," from watches to entire buildings, the greater the need for these devices to store and retrieve massive amounts of data quickly without consuming too much power.
Millions of new memory cells could be part of a computer chip and provide that speed and energy savings, thanks to the discovery of a previously unobserved...
What if, instead of turning up the thermostat, you could warm up with high-tech, flexible patches sewn into your clothes - while significantly reducing your...
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.
The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...
12.12.2018 | Event News
10.12.2018 | Event News
06.12.2018 | Event News
19.12.2018 | Materials Sciences
19.12.2018 | Materials Sciences
19.12.2018 | Life Sciences